Work

Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx366

Authors: M. Lim, A. Omuro, G. Vlahovic, D.A. Reardon, S. Sahebjam, T. Cloughesy, J. Baehring, N. Butowski, V. Potter, R. Zwirtes, P. Paliwal, M. Carleton, J. Sampson, A.A. Brandes

Institutions: Johns Hopkins University, Johns Hopkins Medicine, Memorial Sloan Kettering Cancer Center, Duke Medical Center, Harvard University, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of South Florida, Moffitt Cancer Center, University of California, Los Angeles, Yale University, University of California, San Francisco, Bristol-Myers Squibb (United States)

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, AstraZeneca, Alexion Pharmaceuticals, Genentech, Juno Therapeutics

OpenAlex ID: W2763355542

FWCI: 1.746

Cites:

Cited by: 20

Related to: 10